HOME >> MEDICINE >> NEWS
Metabolic syndrome significantly boosts risk of heart failure in middle age

Metabolic syndrome significantly boosts the chances of heart failure in middle age, suggests research published ahead of print in Heart.

Metabolic syndrome refers to a cluster of conditions, including obesity, high blood pressure, unfavourable blood fat levels, and diabetes.

The researchers base their findings on regular monitoring of more than 2,300 men who were aged 50 between 1970 and 1974 and who were tracked until the age of 70.

The presence of metabolic syndrome at the start of the study was strongly associated with the subsequent development of heart failure. Men with the syndrome were almost twice as likely to develop heart failure as those without.

This was independent of any other established risk factors for heart failure, such as coronary artery disease, a heart attack, smoking, and poorly working heart valves.

The authors suggest that metabolic syndrome may directly affect the heart itself as well as boosting the build up of fatty deposits in the arteries.

The likely mechanism is insulin resistance and the subsequent excess insulin circulating in the blood, say the authors. Insulin may excessively enlarge the heart muscle (myocardium), so impairing its capacity.

High circulating levels of insulin also stimulate the sympathetic nervous system, thought to be a risk factor in heart failure, and cause heart muscle cells to wither and/or stiffen.


'"/>

Contact: Emma Dickinson
edickinson@bmj.com
44-207-383-6529
BMJ Specialty Journals
21-May-2006


Page: 1

Related medicine news :

1. Metabolic study in mice could lead to good cholesterol boosters
2. Metabolic syndrome points to heart health
3. Metabolic disorder not well-suited for inclusion in newborn screening programs
4. Metabolic acidosis associated with an increased mortality rate
5. Metabolic syndrome identified as risk factor for kidney-pancreas transplant patients
6. Metabolic syndrome prevalent in heart attack patients
7. Metabolic side effects of antipsychotics are known, but rarely monitored
8. New nutritional research: College students face obesity, high blood pressure, metabolic syndrome
9. Cedars-Sinai endocrine researchers to discuss gene that may be linked to polycystic ovary syndrome
10. Mayo researchers discover overdiagnosis of long QT heart syndrome
11. Clinical review -- A psychological approach to the management of irritable bowel syndrome

Post Your Comments:
(Date:5/20/2013)... from Comfort & Harmony was featured at ... Association (USLCA) May 2nd – 5th. The conference hosted ... , The USLCA annual conference is a trade ... about the latest trends in lactation. , Mombo ... new mothers use to help support infants while breastfeeding. ...
(Date:5/20/2013)... 2013 Mirena IUD lawsuit ... litigation recently established in U.S. District Court, Southern District ... to court records, the litigation’s first Status Conference was ... Plaintiff’s leadership positions were discussed. So far, at ... District of New York, all of which allege that ...
(Date:5/20/2013)... 2013 Co-founder of Atlanta SEO ... keynote speaker at the 5th International INVEST Domaining & ... brings together company representatives and independent individuals from around ... marketing and investments. , The 2013 conference will take ... México from May 20 to 21. A networking city ...
(Date:5/20/2013)... Nearly 20 percent of kidneys that are recovered ... transplant due to factors ranging from scarring in small ... organ going too long without blood or oxygen. But, ... be "recycled" to help solve the critical shortage of ... Center and colleagues, reporting in the journal Biomaterials ...
(Date:5/20/2013)... 2013 Horizon NJ Health, New Jersey’s ... that it has earned a Commendable Accreditation status ... NJ Health is a wholly owned subsidiary of Horizon ... NCQA Health Plan Accreditation is a nationally recognized program ... health plans provide to their members. Health Plan Accreditation ...
Breaking Medicine News(10 mins):Health News:Comfort & Harmony™ Exhibited mombo™ Nursing Pillow at USLCA’s First Inaugural Conference 2Health News:Mirena IUD Lawsuit News: Bernstein Liebhard LLP Reports on First Status Conference in Federal Mirena Litigation 2Health News:Mirena IUD Lawsuit News: Bernstein Liebhard LLP Reports on First Status Conference in Federal Mirena Litigation 3Health News:EverSpark CEO to be Keynote Speaker at 5th International INVEST Domaining & Internet Marketing Conference in Mexico City 2Health News:Study suggests new source of kidneys for transplant 2Health News:Horizon NJ Health Awarded Commendable Accreditation by NCQA 2Health News:Horizon NJ Health Awarded Commendable Accreditation by NCQA 3
(Date:5/20/2013)... BETHESDA, Md. , May 20, 2013  TNI ... diseases through the activation and mobilization of the body,s ... trading on the OTC Markets, OTCQB marketplace under the ... able to view the real-time Level II stock quotes ... Noreen Griffin , CEO of TNI BioTech, ...
(Date:5/20/2013)... Ill. , May 20, 2013  AbbVie ... initiation of a Phase 3 clinical study called ... assess the effects of the investigational compound atrasentan - ... of kidney disease in patients with stage 2 ... 2 diabetes.  SONAR is a large, multinational, double-blind, ...
(Date:5/19/2013)... , May 20, 2013  Whole-cell pertussis vaccines were ... vaccines during a large recent outbreak, according to a ... Whole-cell pertussis vaccines, also called DTwP, were available from ... concerns that ultimately led to the development of acellular ... late 1990s, the United States ...
Breaking Medicine Technology:TNI BioTech, Inc. Stock to Begin Trading on the OTCQB Marketplace 2TNI BioTech, Inc. Stock to Begin Trading on the OTCQB Marketplace 3AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 2AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 3AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 4AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 5AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 6Study Shows Whole-Cell Vaccine was More Effective than Acellular Vaccine During California Pertussis Outbreak 2Study Shows Whole-Cell Vaccine was More Effective than Acellular Vaccine During California Pertussis Outbreak 3Study Shows Whole-Cell Vaccine was More Effective than Acellular Vaccine During California Pertussis Outbreak 4
Cached News: